CalciMedica (CALC) Income towards Parent Company (2019 - 2026)
CalciMedica's (CALC) quarterly Income towards Parent Company came in at -$5.9 million in Q1 2026, up 14.6% YoY from -$5.2 million in Q1 2025, and down 25.9% on a QoQ basis from -$4.7 million in Q4 2025.
CalciMedica (CALC) Income towards Parent Company (2019 - 2026) Analysis & Trends
CalciMedica (CALC) has 8 years of Income towards Parent Company data on file, last reported at -$5.9 million in Q1 2026.
- Quarterly Income towards Parent Company rose 14.6% year-over-year to -$5.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$26.3 million (up 3.68% YoY) and the FY2025 annual result came in at -$115.8 million, down 2.76% from the prior year.
- Income towards Parent Company declined to -$5.9 million in Q1 2026, from -$4.7 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$2.9 million in Q4 2022 to a low of -$22.7 million in Q1 2023.
- A 5-year average of -$6.7 million and a median of -$6.2 million in 2024 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2023 — Income towards Parent Company slumped 431.13% — and 2024, when it surged 71.13%.
- Tracing CALC's Income towards Parent Company over 5 years: stood at -$2.9 million in 2022, then slumped by 51.76% to -$4.4 million in 2023, then tumbled by 40.43% to -$6.2 million in 2024, then grew by 23.69% to -$4.7 million in 2025, then slipped by 25.9% to -$5.9 million in 2026.
- The last three Income towards Parent Company figures came in at -$5.9 million (Q1 2026), -$4.7 million (Q4 2025), and -$8.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | CalciMedica | 9.80 Mn | -8.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.34 Mn |
| Mar 31, 2026 | -5.93 Mn |
| Dec 31, 2025 | -4.71 Mn |
| Sep 30, 2025 | -8.71 Mn |
| Jun 30, 2025 | -6.95 Mn |
| Mar 31, 2025 | -6.94 Mn |
| Dec 31, 2024 | -6.17 Mn |
| Sep 30, 2024 | -7.02 Mn |
| Jun 30, 2024 | -7.17 Mn |
| Mar 31, 2024 | -6.56 Mn |
| Dec 31, 2023 | -4.40 Mn |
| Sep 30, 2023 | -4.87 Mn |
| Jun 30, 2023 | -7.21 Mn |
| Mar 31, 2023 | -22.71 Mn |
| Dec 31, 2022 | -2.90 Mn |
| Sep 30, 2022 | -3.43 Mn |
| Jun 30, 2022 | -3.94 Mn |
| Mar 31, 2022 | -4.28 Mn |
| Dec 31, 2021 | -8.72 Mn |
| Sep 30, 2021 | -8.52 Mn |